Oncovision is a leading provider of innovative medical imaging devices used by surgeons, radiologists, oncologists and nuclear physicians for the diagnosis and treatment of cancer. Oncovision has grown into a dynamic brand in a technologically competitive, high-growth industry. Oncovision has offices in Boston, USA and Valencia, Spain and sells its products in over 30 markets through a combination of direct sales and distributors. Through a strong internal pipeline, Oncovision boasts a clinical and preclinical product line. Clinical product line includes market-leading Sentinella, a unique intra-operative Gamma Camera and the revolutionary MAMMI PET, a breast cancer diagnostic device capable of visualising lesions of less than 2mm and quantifying tumor activity. Oncovision completes its portfolio with Wprobe, the gold standard in radioguided surgery and Albira a device leading preclinical research to new levels. Oncovision has distinguished itself through the ability to successfully develop and bring to the market innovative products to generate significant benefits on patients, and is committed to continue that trend. Also, the company plans to bring forth technical and clinical solutions for an accurate diagnosis and treatment of cancer, providing the highest-quality, best-performing products.